Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements

Area of Science:

• Neurology
• Clinical Trials
• Biostatistics

Background:

• Cerebellar ataxias often progress slowly, necessitating sensitive quantitative measures for clinical trials.
• Current outcome measures may lack the sensitivity to accurately assess cerebellar dysfunction in these slow-progressing diseases.

Purpose of the Study:

• To evaluate the Composite Cerebellar Functional Severity (CCFS) Scale and the Scale for the Assessment and Rating of Ataxia (SARA) for measuring cerebellar dysfunction.
• To compare the performance of CCFS and SARA in patients with spinocerebellar ataxia (SCA) and Friedreich's ataxia (FRDA) against controls.
• To investigate factors influencing scale scores in different cerebellar ataxia types.

Main Methods:

• Prospective recruitment of patients with Friedreich's ataxia (FRDA), spinocerebellar ataxia (SCA), and healthy controls.
• Evaluation of the Composite Cerebellar Functional Severity (CCFS) Scale and Scale for the Assessment and Rating of Ataxia (SARA).
• Analysis of disease duration, age at onset, and genetic factors (FXN gene repeat length) in relation to scale scores.

Main Results:

• In FRDA, disease duration, age at onset, and FXN gene repeat length explained 31% of CCFS variance and 41% of SARA variance.
• Progression rates (CCFS and SARA scores per year) were lower in FRDA compared to SCA, indicating slower cerebellar dysfunction.
• SCA2 patients exhibited higher CCFS scores than SCA1 and SCA3 patients, with similar SARA scores across these SCA subtypes.

Conclusions:

• Cerebellar dysfunction is more severe in FRDA than SCA, but with slower progression rates as measured by CCFS and SARA.
• Potential ceiling effects for both CCFS and SARA scales at late disease stages.
• The CCFS scale is rater-independent, automated, and suitable for multicenter clinical trials.